157 related articles for article (PubMed ID: 11473532)
21. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
22. Cabergoline.
Colao A; Lombardi G; Annunziato L
Expert Opin Pharmacother; 2000 Mar; 1(3):555-74. PubMed ID: 11249538
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacokinetic/pharmacodynamic analysis of anti-hyperprolactinemic effect of terguride based on dopamine D2 receptor occupancy].
Yamada Y; Irizuki N; Takayanagi R; Yamamoto K; Sawada Y; Iga T
Yakugaku Zasshi; 2003 Apr; 123(4):255-60. PubMed ID: 12704865
[TBL] [Abstract][Full Text] [Related]
24. Hyperprolactinemia after neonatal prolactin (PRL) deficiency in rats: evidence for altered anterior pituitary regulation of PRL secretion.
Shah GV; Shyr SW; Grosvenor CE; Crowley WR
Endocrinology; 1988 May; 122(5):1883-9. PubMed ID: 3129278
[TBL] [Abstract][Full Text] [Related]
25. Effects of bromocriptine and terguride on cell proliferation and apoptosis in the estrogen-stimulated anterior pituitary gland of the rat.
Yonezawa K; Tamaki N; Kokunai T
Neurol Med Chir (Tokyo); 1997 Dec; 37(12):901-6. PubMed ID: 9465588
[TBL] [Abstract][Full Text] [Related]
26. Cabergoline and hyperprolactinaemia: new preparation. Better than bromocriptine.
Prescrire Int; 2000 Feb; 9(45):195-7. PubMed ID: 11503793
[TBL] [Abstract][Full Text] [Related]
27. Use of bromocriptine in hyperprolactinaemic anovulation and related disorders.
Franks S
Drugs; 1979 May; 17(5):337-48. PubMed ID: 378649
[TBL] [Abstract][Full Text] [Related]
28. In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors.
Eguchi K; Kawamoto K; Uozumi T; Ito A; Arita K; Kurisu K
Endocr J; 1995 Apr; 42(2):153-61. PubMed ID: 7627259
[TBL] [Abstract][Full Text] [Related]
29. [Possible mechanisms of the interaction between gonadotropins and prolactin in an experimental hyperprolactinemia model].
Tresguerres JA; Esquifino AI
Acta Physiol Lat Am; 1983; 33(3):257-74. PubMed ID: 6424409
[TBL] [Abstract][Full Text] [Related]
30. Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia.
Larrea F; Sandoval JL; Salinas E; Franco-Rodriguez VA; Méndez I; Ulloa-Aguirre A
Clin Endocrinol (Oxf); 1995 Nov; 43(5):591-600. PubMed ID: 8548944
[TBL] [Abstract][Full Text] [Related]
31. Differential actions of the dopamine agonist bromocriptine on growth of SMtTW tumors exhibiting a prolactin and/or a somatotroph cell phenotype: relation to dopamine D2 receptor expression.
Trouillas J; Chevallier P; Remy C; Rajas F; Cohen R; Calle A; Hooghe-Peters EL; Rousset B
Endocrinology; 1999 Jan; 140(1):13-21. PubMed ID: 9886801
[TBL] [Abstract][Full Text] [Related]
32. Catecholamines and pituitary function. IV. Effects of low-dose dopamine infusion and long-term bromocriptine treatment on the abnormal thyrotroph (TSH) dynamics in patients with pathological hyperprolactinaemia.
Nicoletti I; Filipponi P; Fedeli L; Ambrosi F; Giammartino C; Spinozzi F; Santeusanio F
Acta Endocrinol (Copenh); 1986 Feb; 111(2):154-61. PubMed ID: 3082094
[TBL] [Abstract][Full Text] [Related]
33. [The effect of occult hyperprolactinemia (OHP) on gonadotropin secretion system].
Aisaka K; Yoshida K; Kayama F; Kimura Y; Tamechika S; Satoh K; Matsuoka R; Mori H
Nihon Naibunpi Gakkai Zasshi; 1994 Dec; 70(10):1101-14. PubMed ID: 7859890
[TBL] [Abstract][Full Text] [Related]
34. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
35. Partial hypopituitarism and hyperprolactinemia: successful induction of ovulation with bromocriptine and human menopausal gonadotropins.
Dawood MY; Jarrett JC; Choe JK
Fertil Steril; 1982 Oct; 38(4):415-8. PubMed ID: 6811337
[TBL] [Abstract][Full Text] [Related]
36. Dopamine agonist therapy in hyperprolactinemia.
Webster J
J Reprod Med; 1999 Dec; 44(12 Suppl):1105-10. PubMed ID: 10649819
[TBL] [Abstract][Full Text] [Related]
37. Lysergic acid diethylamide (LSD) is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro.
Giacomelli S; Palmery M; Romanelli L; Cheng CY; Silvestrini B
Life Sci; 1998; 63(3):215-22. PubMed ID: 9698051
[TBL] [Abstract][Full Text] [Related]
38. Dopamine agonist- and antagonist-induced modulation of pituitary gonadotrophin releasing hormone receptors are independent of changes in serum prolactin.
Clayton RN; Bailey LC
J Endocrinol; 1984 Aug; 102(2):215-23. PubMed ID: 6086802
[TBL] [Abstract][Full Text] [Related]
39. Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland.
Oomizu S; Boyadjieva N; Sarkar DK
Alcohol Clin Exp Res; 2003 Jun; 27(6):975-80. PubMed ID: 12824819
[TBL] [Abstract][Full Text] [Related]
40. Dopamine D2 receptor mRNA in the pituitary during the oestrous cycle, pregnancy and lactation in the rat.
Zabavnik J; Wu WX; Eidne KA; McNeilly AS
Mol Cell Endocrinol; 1993 Sep; 95(1-2):121-8. PubMed ID: 8243802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
